Application of Computed Tomography Scanning Parameters Combined with Serum Cripto-1 in the Diagnosis of Renal Cell Carcinoma.

OBJECTIVE: This study aims to analyse the clinical value of computed tomography (CT) scanning parameters combined with serum teratoma-derived growth factor-1 (Cripto-1) in the diagnosis of renal cell carcinoma (RCC). METHODS: A retrospective analysis was conducted on 256 patients with renal tumour admitted to our hospital from July 2020 to December 2022. They were divided into malignant group (n = 180) and benign group (n = 76) based on the final pathological results. All subjects underwent CT scans and serum Cripto-1 testing. The CT signs and serum Cripto-1 levels of the patients were analysed, and their diagnostic efficacy was evaluated. RESULTS: The pathological diagnosis results showed 180 cases of malignant tumours, including 73 cases of clear cell carcinoma, 60 cases of papillary RCC and 47 cases of chromophobe cell carcinoma as well as 76 cases of benign tumour, including 31 cases of renal angiomyolipoma, 25 cases of eosinophilic tumour and 20 cases of renal fibroma. The malignant group had significantly higher incidence of cystic necrosis, uneven enhancement and rapid progression than the benign group (p < 0.01). The incidence of calcification was not statistically different between the two groups (p > 0.05). The malignant group had lower CT value of focus (p < 0.01) and relative corrected CT value of the renal cortex (p < 0.05), and significantly higher serum levels of Cripto-1 (p < 0.01) than the malignant group. The area under the curve of the combined diagnosis was significantly higher than that of serum Cripto-1 alone and comprehensive diagnosis of CT parameters (pcombined diagnosis vs serum Cripto-1 < 0.001, pcombined diagnosis vs comprehensive diagnosis of CT parameters = 0.002). The sensitivity of the combined diagnosis was also higher than that of serum Cripto-1 and CT parameters alone. CONCLUSIONS: The combination of CT scanning parameters and serum Cripto-1 has high value in the diagnosis of renal tumours, and the area under the curve and sensitivity of the combined diagnosis are high. This work provides reference for clinical diagnosis and treatment of renal tumours.

Application of Computed Tomography Scanning Parameters Combined with Serum Cripto-1 in the Diagnosis of Renal Cell Carcinoma

Objective: This study aims to analyse the clinical value of computed tomography (CT) scanning parameters combined with serum teratoma-derived growth factor-1 (Cripto-1) in the diagnosis of renal cell carcinoma (RCC). Methods: A retrospective analysis was conducted on 256 patients with renal tumour admitted to our hospital from July 2020 to December 2022. They were divided into malignant group (n = 180) and benign group (n = 76) based on the final pathological results. All subjects underwent CT scans and serum Cripto-1 testing. The CT signs and serum Cripto-1 levels of the patients were analysed, and their diagnostic efficacy was evaluated. Results: The pathological diagnosis results showed 180 cases of malignant tumours, including 73 cases of clear cell carcinoma, 60 cases of papillary RCC and 47 cases of chromophobe cell carcinoma as well as 76 cases of benign tumour, including 31 cases of renal angiomyolipoma, 25 cases of eosinophilic tumour and 20 cases of renal fibroma. The malignant group had significantly higher incidence of cystic necrosis, uneven enhancement and rapid progression than the benign group (p < 0.01). The incidence of calcification was not statistically different between the two groups (p > 0.05). The malignant group had lower CT value of focus (p < 0.01) and relative corrected CT value of the renal cortex (p < 0.05), and significantly higher serum levels of Cripto-1 (p < 0.01) than the malignant group. The area under the curve of the combined diagnosis was significantly higher than that of serum Cripto-1 alone and comprehensive diagnosis of CT parameters (pcombined diagnosis vs serum Cripto−1 < 0.001, pcombined diagnosis vs comprehensive diagnosis of CT parameters = 0.002). The sensitivity of the combined diagnosis was also higher than that of serum Cripto-1 and CT parameters alone (AU)

Effect of Terazosin Hydrochloride Combined with Interventional Embolisation on Prostate Volume and Quality of Life of Elderly Patients with Prostatic Hyperplasia.

OBJECTIVE: This study aimed to explore the effect of terazosin hydrochloride combined with interventional embolisation on prostate volume and quality of life (QOL) of elderly patients with prostatic hyperplasia (PH). METHODS: The clinical data of 175 elderly patients with PH admitted to Central Hospital Affiliated to Shandong First Medical University from July 2020 to July 2022 were selected for retrospective analysis. Based on different treatment regimens, 89 patients who received interventional embolisation alone were included in the control group (CG), and 86 patients undergoing interventional embolisation combined with terazosin hydrochloride were included in the study group (SG). The prostate volume, serum indicators, adverse reactions and QOL of the two groups before and after treatment were compared between the two groups. RESULTS: Before treatment, no significant difference in 36-item short-form health survey (SF-36) scores, serum tumour necrosis factor-α (TNF-α) and prostate-specific antigen (PSA) was observed in both groups (p > 0.05). After treatment, the SF-36 score in the SG was 78.20 ± 6.84 points, which was significantly higher than that in the CG (72.67 ± 5.94 points). In addition, the SG had remarkably lower residual urine volume and prostate volume, higher maximum flow rate and lower TNF-α and PSA levels compared with the CG (p < 0.05). The adverse reaction rate of the SG was only 4.65%, which was significantly lower than that of the CG (14.61%, p < 0.05). CONCLUSIONS: Terazosin hydrochloride combined with interventional embolisation overtly reduces the prostate volume and improves the clinical symptoms of patients with fewer side effects, which has a certain clinical application value.

Effect of Terazosin Hydrochloride Combined with Interventional Embolisation on Prostate Volume and Quality of Life of Elderly Patients with Prostatic Hyperplasia

Objective: This study aimed to explore the effect of terazosin hydrochloride combined with interventional embolisation on prostate volume and quality of life (QOL) of elderly patients with prostatic hyperplasia (PH). Methods: The clinical data of 175 elderly patients with PH admitted to Central Hospital Affiliated to Shandong First Medical University from July 2020 to July 2022 were selected for retrospective analysis. Based on different treatment regimens, 89 patients who received interventional embolisation alone were included in the control group (CG), and 86 patients undergoing interventional embolisation combined with terazosin hydrochloride were included in the study group (SG). The prostate volume, serum indicators, adverse reactions and QOL of the two groups before and after treatment were compared between the two groups. Results: Before treatment, no significant difference in 36-item short-form health survey (SF-36) scores, serum tumour necrosis factor-α (TNF-α) and prostate-specific antigen (PSA) was observed in both groups (p > 0.05). After treatment, the SF-36 score in the SG was 78.20 ± 6.84 points, which was significantly higher than that in the CG (72.67 ± 5.94 points). In addition, the SG had remarkably lower residual urine volume and prostate volume, higher maximum flow rate and lower TNF-α and PSA levels compared with the CG (p < 0.05). The adverse reaction rate of the SG was only 4.65%, which was significantly lower than that of the CG (14.61%, p < 0.05). Conclusions: Terazosin hydrochloride combined with interventional embolisation overtly reduces the prostate volume and improves the clinical symptoms of patients with fewer side effects, which has a certain clinical application value (AU)

Cox Regression Analysis of Prognostic Factors of Intensity-Modulated Radiotherapy in Patients with Bladder Cancer.

OBJECTIVE: This paper aims to explore the prognostic factors of intensity-modulated radiotherapy (IMRT) in patients with bladder cancer by Cox regression analysis and to provide evidence for prolonging the survival of patients and improving the treatment status. METHODS: A total of 153 cases of patients with bladder cancer who received IMRT were selected as research objects, and their clinical data were retrospectively analyzed and followed up. Kaplan-Meier survival analysis was conducted to calculate the median survival period, univariate and multivariate Cox regression were used to analyze the prognostic factors of IMRT in patients with bladder cancer, and receiver operating characteristic curve was adopted to evaluate the prediction efficiency of influencing factors. RESULTS: Patients were followed up for 9-40 months, and 55 patients died by the end of the follow-up. The median survival time was 30 months, and the 3-year survival rate was 64.05% (98/153). Univariate analysis showed that T stage, total cystectomy, lymph node, pathological type and hydronephrosis influenced the prognosis of IMRT for patients with bladder cancer (p < 0.05). Multivariate Cox regression analysis showed T3 stage (odds ratio (OR) = 0.149, 0.068-0.327), T4 stage (OR = 27.639, 3.677-207.758), lymph node presence (OR = 0.152, 0.050-0.467), pathological type (OR = 0.086, 0.025-0.296) and hydronephrosis (OR = 7.402, 1.161-47.192) were independent factors affecting the prognosis of IMRT in patients with bladder cancer (p < 0.05), while total cystectomy (OR = 1.037, 0.171-6.301) was not an independent factor affecting the prognosis of IMRT in patients with bladder cancer (p > 0.05). CONCLUSIONS: T stage, lymph nodes, nontransitional cell carcinoma with pathological type and hydronephrosis can influence the prognostic effect of IMRT in patients with bladder cancer.

Cox Regression Analysis of Prognostic Factors of Intensity-Modulated Radiotherapy in Patients with Bladder Cancer

Objective: This paper aims to explore the prognostic factors of intensity-modulated radiotherapy (IMRT) in patients with bladder cancer by Cox regression analysis and to provide evidence for prolonging the survival of patients and improving the treatment status. Methods: A total of 153 cases of patients with bladder cancer who received IMRT were selected as research objects, and their clinical data were retrospectively analyzed and followed up. Kaplan–Meier survival analysis was conducted to calculate the median survival period, univariate and multivariate Cox regression were used to analyze the prognostic factors of IMRT in patients with bladder cancer, and receiver operating characteristic curve was adopted to evaluate the prediction efficiency of influencing factors. Results: Patients were followed up for 9–40 months, and 55 patients died by the end of the follow-up. The median survival time was 30 months, and the 3-year survival rate was 64.05% (98/153). Univariate analysis showed that T stage, total cystectomy, lymph node, pathological type and hydronephrosis influenced the prognosis of IMRT for patients with bladder cancer (p < 0.05). Multivariate Cox regression analysis showed T3 stage (odds ratio (OR) = 0.149, 0.068–0.327), T4 stage (OR = 27.639, 3.677–207.758), lymph node presence (OR = 0.152, 0.050–0.467), pathological type (OR = 0.086, 0.025–0.296) and hydronephrosis (OR = 7.402, 1.161–47.192) were independent factors affecting the prognosis of IMRT in patients with bladder cancer (p < 0.05), while total cystectomy (OR = 1.037, 0.171–6.301) was not an independent factor affecting the prognosis of IMRT in patients with bladder cancer (p > 0.05). Conclusions: T stage, lymph nodes, nontransitional cell carcinoma with pathological type and hydronephrosis can influence the prognostic effect of IMRT in patients with bladder cancer (AU)

Association of blood cobalt concentrations with dyslipidemia, hypertension, and diabetes in a US population: A cross-sectional study.

ABSTRACT: Various heavy metal elements in the human body have been reported to be associated with dyslipidemia, hypertension, and diabetes. The role of cobalt in these conditions is unclear. The current study aimed to investigate the association of blood cobalt concentrations with dyslipidemia, hypertension, and diabetes.Using the data collected from the National Health and Nutrition Examination Survey (2015-2018), we performed logistic regression to explore the association of blood cobalt concentrations with total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, hypertension, and diabetes.A total of 6866 adults were included in this study. Participants with higher blood cobalt levels appeared to be older and have a lower body mass index and, were more likely to be female (P for trend < .05). After fully adjusting for demographic characteristics (Model 2), compared with the lowest quartile, the highest quartile of blood cobalt concentrations had lower odds ratios (ORs) for elevated TC [OR: 0.62, 95% confidential interval (CI): 0.53 to 0.72, P < .001], elevated LDL-C (OR: 0.65, 95% CI: 0.53-0.80, P < .001) and low HDL-C (OR: 0.81, 95% CI: 0.69-0.96, P = .013). The adjusted ORs for elevated TC, elevated LDL-C and low HDL-C were negatively correlated with increased blood cobalt concentrations (P for trend < .05). The adjusted ORs for hypertension and diabetes were not associated with blood cobalt concentrations (P > .05 and P for trend > .05).In conclusion, higher blood cobalt concentrations were associated with a lower risk of dyslipidemia. However, blood cobalt concentrations were not associated with the risk of hypertension or diabetes.